Proceedings: Moving Toward Cell-Based Therapies for Liver Disease

Kadyk, Lisa C.; Collins, Lila R.; Littman, Neil; Millan, Maria T.

doi:10.5966/sctm.2014-0276

Cited by 25 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell-based therapies are a promising alternative strategy to liver organ transplantation for the treatment of liver disease ( 1 , 2 ). Stem or progenitor cells have been considered as potential sources of cells for hepatocyte replacement and functional recovery due to their characteristics of self-renewal, generation of progeny and multiple-differentiation ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Periodic acid-Schiff staining method for function detection of liver cells is affected by 2% horse serum in induction medium

Hui

Cui

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Developing a thorough understanding of experimental methods of hepatic differentiation in hepatic progenitor cells (HPCs) should expand the knowledge of hepatocyte induction in vitro and may help to develop cell transplantation therapies for the clinical usage of HPCs in liver diseases. A previous induction method effectively induced differentiation and metabolic abilities in HPCs. Periodic acid-Schiff (PAS) staining is used to identify glycogen synthesis and hepatocyte function; however, this method failed to detect induced hepatocytes. The present study aimed to investigate the possible factors affecting the previous confusing results of PAS staining. Removal of single induction factors, including dexamethasone, hepatic growth factor and fibroblast growth factor 4 from the induction media did not restore PAS staining, whereas replacement of 2% horse serum (HS) with 10% fetal bovine serum (FBS) significantly increased the number of PAS positive cells. Following 12 days of basal induction, replacing the induction medium with media containing 10% FBS for 12–72 h significantly improved PAS staining, but did not influence indocyanine green uptake. Furthermore, incubation in induction medium with 10% FBS following 12 days of normal induction did not affect the expression of hepatic markers and mature function of HPCs. Therefore, the present study suggested that 2% HS in the induction medium did not affect the hepatic function of induced cells, but did affect glycogen storage, whereas replacement of medium with 10% FBS in advance of PAS staining may restore the failure of PAS staining in low serum concentrations of induced hepatocytes.

show abstract

Section: Introductionmentioning

confidence: 99%

Periodic acid-Schiff staining method for function detection of liver cells is affected by 2% horse serum in induction medium

Hui

Cui

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Every year, in the United States, of the 15 000 people waiting for a liver transplant, 10% die [ 2 ]. Procedures such as hepatocyte transplantation and use of bioartificial liver devices could represent feasible therapies bridging the time for whole organ transplantation or supporting the regeneration of the liver [ 3 ]. All these alternatives require an adequate source of functional hepatocytes.…”

Section: Introductionmentioning

confidence: 99%

Liver tissue fragments obtained from males are the most promising source of human hepatocytes for cell-based therapies – Flow cytometric analysis of albumin expression

et al. 2017

View full text Add to dashboard Cite

Cell-based therapies that could provide an alternative treatment for the end-stage liver disease require an adequate source of functional hepatocytes. There is little scientific evidence for the influence of patient’s age, sex, and chemotherapy on the cell isolation efficiency and metabolic activity of the harvested hepatocytes. The purpose of this study was to investigate whether hepatocytes derived from different sources display differential viability and biosynthetic capacity. Liver cells were isolated from 41 different human tissue specimens. Hepatocytes were labeled using specific antibodies and analyzed using flow cytometry. Multiparametric analysis of the acquired data revealed statistically significant differences between some studied groups of patients. Generally, populations of cells isolated from the male specimens had greater percentage of biosynthetically active hepatocytes than those from the female ones regardless of age and previous chemotherapy of the patient. Based on the albumin staining (and partially on the α-1-antitrypsin labeling) after donor liver exclusion (6 out of 41 samples), our results indicated that: 1. samples obtained from males gave a greater percentage of active hepatocytes than those from females (p = 0.034), and 2. specimens from the males after chemotherapy greater than those from the treated females (p = 0.032).

show abstract

“…However, current research is intended to overcome the problem of immune rejection associated with allogeneic sources and focuses on therapies based on generation of autologous hepatocytes from MSCs and induced pluripotent stem cells (iPSCs) [5]. Elucidation of cell type, which can be successfully differentiated into functional and transplantable hepatocytes or liver progenitor cells, is another major task under study [7]. Furthermore, researchers are trying to refine protocols for proliferation, differentiation, and storage of these cells to have them in plenty and always ready to be transplanted.…”

Section: Advancements In the Field Of Regenerative Medicine Open Up Nmentioning

confidence: 99%

Regenerative Medicine in Liver Cirrhosis: Promises and Pitfalls

Tayyeb¹,

Azam²,

Nisar³

et al. 2017

Liver Cirrhosis - Update and Current Challenges

View full text Add to dashboard Cite

Liver cirrhosis is irreversible and mostly ends up with complete loss of liver function/ end-stage liver failure, and the only proven treatment is liver transplantation. Scarcity of donor, high cost, lifelong immunosuppression, and surgical complications are the major issues associated with liver transplantation and these urge to look for alternate therapeutic approaches. Advancements in the field of regenerative medicine are arising hope for the treatment of liver cirrhosis. This chapter deals with the scope of liver regenerative medicine in the treatment of liver cirrhosis. Review of the literature showed that liver regenerative medicine no doubt holds great promises and added a lot of hope to the cure of liver diseases. Primarily, cell-based therapies had shown great potential to treat liver cirrhosis. Successful clinical human trials further strengthen their significance in the field. However, recent trends in liver regenerative medicine are focusing on the development of tissue engineering leading to generation of the whole organ. Despite advantages, liver regenerative medicine has several limitations and sometimes been over-optimistically interpreted. In conclusion, the current scenario advocates to conduct more preclinical and clinical trials to effectively replace liver transplantation with liver regenerative medicine to treat liver diseases.

show abstract

Proceedings: Moving Toward Cell-Based Therapies for Liver Disease

Cited by 25 publications

References 13 publications

Periodic acid-Schiff staining method for function detection of liver cells is affected by 2% horse serum in induction medium

Periodic acid-Schiff staining method for function detection of liver cells is affected by 2% horse serum in induction medium

Liver tissue fragments obtained from males are the most promising source of human hepatocytes for cell-based therapies – Flow cytometric analysis of albumin expression

Regenerative Medicine in Liver Cirrhosis: Promises and Pitfalls

Contact Info

Product

Resources

About